After treatment with αIIbβ3 antagonist, abciximab, the release of platelet-derived vascular endothelial growth factor and the adhesion of platelets to tumor cells are significantly impaired, restricting the extravasation of tumor cells, thus inhibiting metastasis [139]. This evidence concerns the gene VEGFA and neoplasm.